Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22334Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Florentin, M. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.date.accessioned | 2015-11-24T19:23:34Z | - |
| dc.date.available | 2015-11-24T19:23:34Z | - |
| dc.identifier.issn | 1873-4286 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22334 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Anti-Obesity Agents/*therapeutic use | en |
| dc.subject | Anticholesteremic Agents/therapeutic use | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Dyslipidemias/*drug therapy/*etiology | en |
| dc.subject | Humans | en |
| dc.subject | Hypolipidemic Agents/*therapeutic use | en |
| dc.subject | Metabolic Syndrome X/*complications/*drug therapy | en |
| dc.subject | Obesity/*drug therapy/*etiology | en |
| dc.title | Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/19860690 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2009 | - |
| heal.abstract | Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially combinations of different drugs, in order to tackle all the features of MetS. We review the therapeutic strategies currently used for obesity and dyslipidemia treatment in patients with MetS, with a focus on drug combinations. | en |
| heal.journalName | Curr Pharm Des | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
